Craniopharyngioma
Conditions
Keywords
Brain tumor, Pediatrics, Radiation therapy, Proton therapy, Surgery
Brief summary
Craniopharyngioma is a rare brain tumor that affects both children and adults. It arises in a region of the brain near the pituitary gland, visual pathways, and central blood vessels. Patients often present with headache, loss of vision or delayed growth. In some instances they may present with imbalance of water and salts in the body. The treatment for craniopharyngioma may be radical surgery or a combination of surgery and radiation therapy. In some instances surgery is not required. If the tumor cannot be completely removed, radiation therapy may be required. In this study we will use the most advanced form of proton therapy which is called intensity-modulated proton therapy. This is a newer form of radiation therapy which has a number of advantages over older forms of proton therapy and conventional radiation therapy using x-rays. The main goal of this study is to learn if proton therapy will effectively treat patients with craniopharyngioma brain tumors and reduce side effects compared to more traditional forms of radiation therapy.
Detailed description
This study will include participants who are diagnosed or presumed to have craniopharyngioma based on neuroimaging, intra-operative assessment, or the evaluation of cyst fluid or tissue after limited or radical surgery. When possible, participants will be enrolled on protocol prior to surgery. PRIMARY OBJECTIVE: * To estimate the distributions of progression-free and overall survival for children and young adults with craniopharyngioma treated with intensity-modulated proton therapy while monitoring for excessive central nervous system necrosis, clinically significant vasculopathy, and permanent neurological conditions or deficits. SECONDARY OBJECTIVES: * To estimate the cumulative incidence of cystic intervention and the event-free survival distribution for children and young adults with craniopharyngioma treated with intensity-modulated proton therapy; and to compare the distributions of progression-free, event-free and overall survival with the distributions for the St. Jude Children's Research Hospital (SJCRH) cohort of patients treated with photon therapy on which the design of this trial is based. * To estimate the cumulative incidence of cystic intervention and the distributions of progression-free survival, overall survival and the event-free survival for children and young adults with craniopharyngioma treated only with primary surgical resection and to compare these distributions with the distributions observed for patients treated with proton therapy. OTHER PRE-SPECIFIED OBJECTIVES: * To explore potential associations of clinical and treatment factors with the incidence and severity of neurological, endocrine and cognitive deficits in children and young adults with craniopharyngioma treated with radical surgery or proton therapy. Descriptively compare findings for patients treated with proton therapy with the reported findings for the updated SJCRH cohort treated with photon therapy. * Using specific measures of sleep quality, excessive daytime sleepiness, daytime activity, circadian rhythm, fatigue, symptom distresses, and quality of life, explore associations of sleep, fatigue and quality of life with other measures of central nervous system (CNS) effects, clinical and treatment factors in children and young adults with craniopharyngioma treated with radical surgery or proton therapy. * To evaluate and explore differences in physical performance and movement in children and young adults with craniopharyngioma treated with radical surgery or proton therapy, using specific measures of overall physical performance, flexibility, balance, coordination, muscle strength and power, and cardiopulmonary fitness. * Estimate and compare the response of residual tumor and the incidence and severity of structural, functional and vascular effects of normal brain in children and young adults with craniopharyngioma after treatment with radical surgery or proton therapy using specific methods of diffusion, contrast-enhancement, vascular and functional neuroimaging, and explore the association between these and other measures of CNS effects and clinical and treatment factors. * Investigate the feasibility of using positron emission tomography (PET) as an in vivo dose and distal edge verification system for craniopharyngioma patients treated with proton therapy. * Measure growth factor and cytokine responses in children and young adults with craniopharyngioma after treatment with radical surgery or proton therapy, and explore associations between these and other measures of CNS effects and clinical and treatment factors. Descriptively compare findings for patients treated with proton therapy with the reported findings for the updated SJCRH cohort treated with photon therapy.
Interventions
RADIATIONProton Therapy
The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
PROCEDURESurgery
When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
Sponsors
St. Jude Children's Research Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* Craniopharyngioma diagnosed by histology, cytology or neuroimaging or intra-operative assessment * Patients ages 0-21 years at the time of diagnosis
Exclusion criteria
* Prior history of fractionated radiation therapy * Prior treatment with intracystic P-32 or intracystic bleomycin * Pregnant females are excluded. Radiation has teratogenic or abortifacient effects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 3 years after initiation of proton therapy | PFS is defined as the interval of time from the initiation of radiation therapy (RT) until the earliest of the events: death from any cause; and disease progression. |
| Overall survival (OS) | 3 years after initiation of proton therapy | OS is defined as the interval of time from the initiation of RT until the death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare incidence of first cystic intervention with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital | 3 years after initiation of proton therapy | The cumulative incidence estimates of first cystic intervention for cystic fluctuations after proton therapy. Competing events are death, disease progression and development of a new or secondary tumor. |
| Compare event-free survival (EFS) with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital | 3 years after initiation of proton therapy | Kaplan-Meier estimates will be provided of EFS, which is measured from initiation of proton therapy until the earliest of PFS failure or secondary malignancy or new tumor, or surgical intervention for cystic fluctuation. Patients who have not experienced an event will be censored at their last date of contact. |
| Compare survival distributions with participants treated with conventional radiation therapy at St. Jude Children's Research Hospital | 3 years after initiation of proton therapy | Final analyses will also compare survival distributions using the log-rank test for patients treated with limited surgery and proton therapy on this protocol with the updated SJCRH cohort of patients treated with limited surgery and photon irradiation. The definition of survival will be defined in same way for both cohorts. This secondary analysis will be stratified by whether or not patients have a cerebrospinal fluid (CSF) shunt in place prior to irradiation and race (black versus white). |
| Compare survival distributions between groups | 3 years after initiation of proton therapy | To estimate the survival distributions for children and young adults with craniopharyngioma treated only with primary surgical resection and to compare these distributions with the distributions observed for patients treated with limited surgery and proton therapy. A stratified log-rank test will be used to compare the distributions for children and young adults with craniopharyngioma treated only with primary surgical resection and the distributions observed for patients treated with limited surgery and proton therapy. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORThomas E. Merchant, DO, PhD
St. Jude Children's Research Hospital
Outcome results
None listed